mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Colorectal cancers (CRCs) harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug screen, we have developed a novel therapeutic strategy that combines targeting of the apoptotic machinery using the BCL-2 family inhibitor ABT-263 (navitocl...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Faber, Anthony C., Coffee, Erin M., Costa, Carlotta, Dastur, Anahita, Ebi, Hiromichi, Hata, Aaron N., Yeo, Alan T., Edelman, Elena J., Song, Youngchul, Tam, Ah Ting, Boisvert, Jessica L., Milano, Randy J., Roper, Jatin, Kodack, David P., Jain, Rakesh K., Corcoran, Ryan B., Rivera, Miguel N., Ramaswamy, Sridhar, Hung, Kenneth E., Benes, Cyril H., Engelman, Jeffrey A.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3973435/
https://ncbi.nlm.nih.gov/pubmed/24163374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0315
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires